 | • レポートコード：QYR9ST01148 • 出版社/出版日：QYResearch / 2019年9月2日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| ※本調査レポートでは、世界の肺動脈性肺高血圧症治療市場について調査・分析し、以下の構成でお届け致します。肺動脈性肺高血圧症治療の種類別には、血管拡張薬、ホスホジエステラーゼ5（PDE 5）阻害薬、エンドセリン受容体拮抗薬（ERA）、可溶性グアニル酸シクラーゼ（SGC）刺激薬に、用途別には、病院薬局、小売薬局、オンライン薬局に、地域別には、北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカなどに区分してセグメント分析を行いました。 ・調査販売 ・エグゼクティブ・サマリー ・企業別肺動脈性肺高血圧症治療売上データ ・地域別肺動脈性肺高血圧症治療市場規模：北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカ、その他 ・種類別肺動脈性肺高血圧症治療市場規模：血管拡張薬、ホスホジエステラーゼ5（PDE 5）阻害薬、エンドセリン受容体拮抗薬（ERA）、可溶性グアニル酸シクラーゼ（SGC）刺激薬 ・用途別肺動脈性肺高血圧症治療市場規模：病院薬局、小売薬局、オンライン薬局 ・主要メーカーの企業情報：GlaxoSmithKline plc、Eli Lilly and Company、Pfizer Inc.Actelion Inc、United Therapeutic Corporation、SteadyMed Ltd、Gilead Sciences, Inc、Teva Pharmaceuticals Inc、Bayer AG ・肺動脈性肺高血圧症治療の市場規模予測 ・バリューチェーン及び販売チャネル分析 ・市場機会・課題・リスク・影響因子分析 ... |
Pulmonary arterial hypertension- commonly known as PAH- is characterized by increased pressure in the pulmonary arteries due to structural changes in blood vessel walls, aggregation of platelets and alteration of smooth muscle cell function- eventually elevating pressure in the pulmonary arteries responsible for pumping blood to the lungs. This eventually leads to right heart failure and, ultimately, death.The global Pulmonary Arterial Hypertension Treatment market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Pulmonary Arterial Hypertension Treatment market based on company, product type, end user and key regions.
This report studies the global market size of Pulmonary Arterial Hypertension Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Pulmonary Arterial Hypertension Treatment in these regions.
This research report categorizes the global Pulmonary Arterial Hypertension Treatment market by top players/brands, region, type and end user. This report also studies the global Pulmonary Arterial Hypertension Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
GlaxoSmithKline plc
Eli Lilly and Company
Pfizer Inc.Actelion Inc
United Therapeutic Corporation
SteadyMed Ltd
Gilead Sciences, Inc
Teva Pharmaceuticals Inc
Bayer AG
Market size by Product
Vasodilators
Phosphodiesterase 5 (PDE 5) Inhibitors
Endothelin Receptor Antagonists (ERA)
Soluble Guanylate Cyclase (SGC) Stimulator
Market size by End User
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Pulmonary Arterial Hypertension Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Pulmonary Arterial Hypertension Treatment market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Pulmonary Arterial Hypertension Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Pulmonary Arterial Hypertension Treatment submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Pulmonary Arterial Hypertension Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Pulmonary Arterial Hypertension Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
レポート目次Table of Contents
1 Study Coverage
1.1 Pulmonary Arterial Hypertension Treatment Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by Product
1.4.2 Vasodilators
1.4.3 Phosphodiesterase 5 (PDE 5) Inhibitors
1.4.4 Endothelin Receptor Antagonists (ERA)
1.4.5 Soluble Guanylate Cyclase (SGC) Stimulator
1.5 Market by End User
1.5.1 Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by End User
1.5.2 Hospital Pharmacies
1.5.3 Retail Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Pulmonary Arterial Hypertension Treatment Market Size
2.1.1 Global Pulmonary Arterial Hypertension Treatment Revenue 2014-2025
2.1.2 Global Pulmonary Arterial Hypertension Treatment Sales 2014-2025
2.2 Pulmonary Arterial Hypertension Treatment Growth Rate by Regions
2.2.1 Global Pulmonary Arterial Hypertension Treatment Sales by Regions
2.2.2 Global Pulmonary Arterial Hypertension Treatment Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Pulmonary Arterial Hypertension Treatment Sales by Manufacturers
3.1.1 Pulmonary Arterial Hypertension Treatment Sales by Manufacturers
3.1.2 Pulmonary Arterial Hypertension Treatment Sales Market Share by Manufacturers
3.1.3 Global Pulmonary Arterial Hypertension Treatment Market Concentration Ratio (CR5 and HHI)
3.2 Pulmonary Arterial Hypertension Treatment Revenue by Manufacturers
3.2.1 Pulmonary Arterial Hypertension Treatment Revenue by Manufacturers (2014-2019)
3.2.2 Pulmonary Arterial Hypertension Treatment Revenue Share by Manufacturers (2014-2019)
3.3 Pulmonary Arterial Hypertension Treatment Price by Manufacturers
3.4 Pulmonary Arterial Hypertension Treatment Manufacturing Base Distribution, Product Types
3.4.1 Pulmonary Arterial Hypertension Treatment Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Pulmonary Arterial Hypertension Treatment Product Type
3.4.3 Date of International Manufacturers Enter into Pulmonary Arterial Hypertension Treatment Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Pulmonary Arterial Hypertension Treatment Sales by Product
4.2 Global Pulmonary Arterial Hypertension Treatment Revenue by Product
4.3 Pulmonary Arterial Hypertension Treatment Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Pulmonary Arterial Hypertension Treatment Breakdown Data by End User
6 North America
6.1 North America Pulmonary Arterial Hypertension Treatment by Countries
6.1.1 North America Pulmonary Arterial Hypertension Treatment Sales by Countries
6.1.2 North America Pulmonary Arterial Hypertension Treatment Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Pulmonary Arterial Hypertension Treatment by Product
6.3 North America Pulmonary Arterial Hypertension Treatment by End User
7 Europe
7.1 Europe Pulmonary Arterial Hypertension Treatment by Countries
7.1.1 Europe Pulmonary Arterial Hypertension Treatment Sales by Countries
7.1.2 Europe Pulmonary Arterial Hypertension Treatment Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Pulmonary Arterial Hypertension Treatment by Product
7.3 Europe Pulmonary Arterial Hypertension Treatment by End User
8 Asia Pacific
8.1 Asia Pacific Pulmonary Arterial Hypertension Treatment by Countries
8.1.1 Asia Pacific Pulmonary Arterial Hypertension Treatment Sales by Countries
8.1.2 Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Pulmonary Arterial Hypertension Treatment by Product
8.3 Asia Pacific Pulmonary Arterial Hypertension Treatment by End User
9 Central & South America
9.1 Central & South America Pulmonary Arterial Hypertension Treatment by Countries
9.1.1 Central & South America Pulmonary Arterial Hypertension Treatment Sales by Countries
9.1.2 Central & South America Pulmonary Arterial Hypertension Treatment Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Pulmonary Arterial Hypertension Treatment by Product
9.3 Central & South America Pulmonary Arterial Hypertension Treatment by End User
10 Middle East and Africa
10.1 Middle East and Africa Pulmonary Arterial Hypertension Treatment by Countries
10.1.1 Middle East and Africa Pulmonary Arterial Hypertension Treatment Sales by Countries
10.1.2 Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Pulmonary Arterial Hypertension Treatment by Product
10.3 Middle East and Africa Pulmonary Arterial Hypertension Treatment by End User
11 Company Profiles
11.1 GlaxoSmithKline plc
11.1.1 GlaxoSmithKline plc Company Details
11.1.2 Company Business Overview
11.1.3 GlaxoSmithKline plc Pulmonary Arterial Hypertension Treatment Sales, Revenue and Gross Margin (2014-2019)
11.1.4 GlaxoSmithKline plc Pulmonary Arterial Hypertension Treatment Products Offered
11.1.5 GlaxoSmithKline plc Recent Development
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Details
11.2.2 Company Business Overview
11.2.3 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Products Offered
11.2.5 Eli Lilly and Company Recent Development
11.3 Pfizer Inc.Actelion Inc
11.3.1 Pfizer Inc.Actelion Inc Company Details
11.3.2 Company Business Overview
11.3.3 Pfizer Inc.Actelion Inc Pulmonary Arterial Hypertension Treatment Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Pfizer Inc.Actelion Inc Pulmonary Arterial Hypertension Treatment Products Offered
11.3.5 Pfizer Inc.Actelion Inc Recent Development
11.4 United Therapeutic Corporation
11.4.1 United Therapeutic Corporation Company Details
11.4.2 Company Business Overview
11.4.3 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Sales, Revenue and Gross Margin (2014-2019)
11.4.4 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Products Offered
11.4.5 United Therapeutic Corporation Recent Development
11.5 SteadyMed Ltd
11.5.1 SteadyMed Ltd Company Details
11.5.2 Company Business Overview
11.5.3 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Sales, Revenue and Gross Margin (2014-2019)
11.5.4 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Products Offered
11.5.5 SteadyMed Ltd Recent Development
11.6 Gilead Sciences, Inc
11.6.1 Gilead Sciences, Inc Company Details
11.6.2 Company Business Overview
11.6.3 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Products Offered
11.6.5 Gilead Sciences, Inc Recent Development
11.7 Teva Pharmaceuticals Inc
11.7.1 Teva Pharmaceuticals Inc Company Details
11.7.2 Company Business Overview
11.7.3 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Products Offered
11.7.5 Teva Pharmaceuticals Inc Recent Development
11.8 Bayer AG
11.8.1 Bayer AG Company Details
11.8.2 Company Business Overview
11.8.3 Bayer AG Pulmonary Arterial Hypertension Treatment Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Bayer AG Pulmonary Arterial Hypertension Treatment Products Offered
11.8.5 Bayer AG Recent Development
12 Future Forecast
12.1 Pulmonary Arterial Hypertension Treatment Market Forecast by Regions
12.1.1 Global Pulmonary Arterial Hypertension Treatment Sales Forecast by Regions 2019-2025
12.1.2 Global Pulmonary Arterial Hypertension Treatment Revenue Forecast by Regions 2019-2025
12.2 Pulmonary Arterial Hypertension Treatment Market Forecast by Product
12.2.1 Global Pulmonary Arterial Hypertension Treatment Sales Forecast by Product 2019-2025
12.2.2 Global Pulmonary Arterial Hypertension Treatment Revenue Forecast by Product 2019-2025
12.3 Pulmonary Arterial Hypertension Treatment Market Forecast by End User
12.4 North America Pulmonary Arterial Hypertension Treatment Forecast
12.5 Europe Pulmonary Arterial Hypertension Treatment Forecast
12.6 Asia Pacific Pulmonary Arterial Hypertension Treatment Forecast
12.7 Central & South America Pulmonary Arterial Hypertension Treatment Forecast
12.8 Middle East and Africa Pulmonary Arterial Hypertension Treatment Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Pulmonary Arterial Hypertension Treatment Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Figure Pulmonary Arterial Hypertension Treatment Product Picture
Table Pulmonary Arterial Hypertension Treatment Market Segments
Table Key Manufacturers Pulmonary Arterial Hypertension Treatment Covered
Table Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by Product 2019-2025 (K Units) & (Million US$)
Figure Global Pulmonary Arterial Hypertension Treatment Sales Market Share by Product 2014-2025
Figure Vasodilators Product Picture
Table Major Manufacturers of Vasodilators
Figure Phosphodiesterase 5 (PDE 5) Inhibitors Product Picture
Table Major Manufacturers of Phosphodiesterase 5 (PDE 5) Inhibitors
Figure Endothelin Receptor Antagonists (ERA) Product Picture
Table Major Manufacturers of Endothelin Receptor Antagonists (ERA)
Figure Soluble Guanylate Cyclase (SGC) Stimulator Product Picture
Table Major Manufacturers of Soluble Guanylate Cyclase (SGC) Stimulator
Table Global Pulmonary Arterial Hypertension Treatment Market Size Growth Rate by End User 2019-2025 (K Units)
Figure Hospital Pharmacies
Figure Retail Pharmacies
Figure Online Pharmacies
Figure Pulmonary Arterial Hypertension Treatment Report Years Considered
Figure Global Pulmonary Arterial Hypertension Treatment Market Size 2014-2025 (Million US$)
Figure Global Pulmonary Arterial Hypertension Treatment Sales 2014-2025 (K Units)
Table Global Pulmonary Arterial Hypertension Treatment Market Size by Regions 2014-2019 (K Units) & (Million US$)
Table Global Pulmonary Arterial Hypertension Treatment Sales by Regions 2014-2019 (K Units)
Table Global Pulmonary Arterial Hypertension Treatment Sales Market Share by Regions 2014-2019
Figure Global Pulmonary Arterial Hypertension Treatment Sales Market Share by Regions 2014-2019
Figure 2018 Global Pulmonary Arterial Hypertension Treatment Sales Market Share by Regions
Table Global Pulmonary Arterial Hypertension Treatment Revenue by Regions 2014-2019 (Million US$)
Table Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Regions 2014-2019
Figure Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Regions 2014-2019
Figure 2018 Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Regions
Table Global Pulmonary Arterial Hypertension Treatment Sales by Manufacturers (2014-2019) (K Units)
Table Global Pulmonary Arterial Hypertension Treatment Sales Share by Manufacturers (2014-2019)
Figure Global Pulmonary Arterial Hypertension Treatment Sales Share by Manufacturers in 2018
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Pulmonary Arterial Hypertension Treatment Revenue by Manufacturers (2014-2019) (Million USD)
Table Pulmonary Arterial Hypertension Treatment Revenue Share by Manufacturers (2014-2019)
Figure Pulmonary Arterial Hypertension Treatment Value Share by Manufacturers in 2018
Table Key Manufacturers Pulmonary Arterial Hypertension Treatment Price (2014-2019) (USD/Unit)
Table Pulmonary Arterial Hypertension Treatment Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers Pulmonary Arterial Hypertension Treatment Product Type
Table Date of International Manufacturers Enter into Pulmonary Arterial Hypertension Treatment Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global Pulmonary Arterial Hypertension Treatment Sales by Product (2014-2019) (K Units)
Table Global Pulmonary Arterial Hypertension Treatment Sales Share by Product (2014-2019)
Figure Global Pulmonary Arterial Hypertension Treatment Sales Market Share by Product (2014-2019)
Figure Global Pulmonary Arterial Hypertension Treatment Sales Market Share by Product in 2018
Table Global Pulmonary Arterial Hypertension Treatment Revenue by Product (2014-2019) (Million US$)
Table Global Pulmonary Arterial Hypertension Treatment Revenue Share by Product (2014-2019)
Figure Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Product (2014-2019)
Figure Global Pulmonary Arterial Hypertension Treatment Revenue Market Share by Product in 2018
Table Pulmonary Arterial Hypertension Treatment Price by Product 2014-2019 (USD/Unit)
Table Global Pulmonary Arterial Hypertension Treatment Sales by End User (2014-2019) (K Units)
Table Global Pulmonary Arterial Hypertension Treatment Sales Share by End User (2014-2019)
Figure Global Sales Pulmonary Arterial Hypertension Treatment Market Share by End User (2014-2019)
Figure Global Sales Pulmonary Arterial Hypertension Treatment Market Share by End User in 2018
Figure North America Pulmonary Arterial Hypertension Treatment Sales Growth Rate 2014-2019 (K Units)
Figure North America Pulmonary Arterial Hypertension Treatment Revenue Growth Rate 2014-2019 (Million US$)
Table North America Pulmonary Arterial Hypertension Treatment Sales by Countries (2014-2019) (K Units)
Table North America Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries (2014-2019)
Figure 2018 North America Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries
Table North America Pulmonary Arterial Hypertension Treatment Revenue by Countries (2014-2019) (Million US$)
Table North America Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries (2014-2019)
Figure 2018 North America Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries
Figure United States Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure United States Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (K Units)
Figure Canada Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Canada Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure Mexico Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Mexico Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Table North America Pulmonary Arterial Hypertension Treatment Sales by Product (2014-2019) (K Units)
Table North America Pulmonary Arterial Hypertension Treatment Sales Market Share by Product (2014-2019)
Figure 2018 North America Pulmonary Arterial Hypertension Treatment Market Share by Product
Table North America Pulmonary Arterial Hypertension Treatment Sales by End User (2014-2019) (K Units)
Table North America Pulmonary Arterial Hypertension Treatment Sales Market Share by End User (2014-2019)
Figure 2018 North America Pulmonary Arterial Hypertension Treatment Market Share by End User
Figure Europe Pulmonary Arterial Hypertension Treatment Sales Growth Rate 2014-2019 (K Units)
Figure Europe Pulmonary Arterial Hypertension Treatment Revenue Growth Rate 2014-2019 (Million US$)
Table Europe Pulmonary Arterial Hypertension Treatment Sales by Countries (2014-2019) (K Units)
Table Europe Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries (2014-2019)
Figure 2018 Europe Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries
Table Europe Pulmonary Arterial Hypertension Treatment Revenue by Countries (2014-2019) (Million US$)
Table Europe Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries (2014-2019)
Figure 2018 Europe Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries
Figure Germany Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Germany Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure France Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure France Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure UK Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure UK Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure Italy Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Italy Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure Russia Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Russia Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Table Europe Pulmonary Arterial Hypertension Treatment Sales by Product (2014-2019) (K Units)
Table Europe Pulmonary Arterial Hypertension Treatment Sales Market Share by Product (2014-2019)
Figure 2018 Europe Pulmonary Arterial Hypertension Treatment Market Share by Product
Table Europe Pulmonary Arterial Hypertension Treatment Sales by End User (2014-2019) (K Units)
Table Europe Pulmonary Arterial Hypertension Treatment Sales Market Share by End User (2014-2019)
Figure 2018 Europe Pulmonary Arterial Hypertension Treatment Market Share by End User
Figure Asia Pacific Pulmonary Arterial Hypertension Treatment Sales Growth Rate 2014-2019 (K Units)
Figure Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue Growth Rate 2014-2019 (Million US$)
Table Asia Pacific Pulmonary Arterial Hypertension Treatment Sales by Countries (2014-2019) (K Units)
Table Asia Pacific Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries
Table Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue by Countries (2014-2019) (Million US$)
Table Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries
Figure China Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure China Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure Japan Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Japan Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure Korea Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Korea Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure India Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure India Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure Australia Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Australia Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure Indonesia Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Indonesia Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure Malaysia Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Malaysia Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure Philippines Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Philippines Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure Thailand Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Thailand Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure Vietnam Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Vietnam Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure Singapore Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Singapore Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Table Asia Pacific Pulmonary Arterial Hypertension Treatment Sales by Product (2014-2019) (K Units)
Table Asia Pacific Pulmonary Arterial Hypertension Treatment Sales Market Share by Product (2014-2019)
Figure 2018 Asia Pacific Pulmonary Arterial Hypertension Treatment Market Share by Product
Table Asia Pacific Pulmonary Arterial Hypertension Treatment Sales by End User (2014-2019) (K Units)
Table Asia Pacific Pulmonary Arterial Hypertension Treatment Sales Market Share by End User (2014-2019)
Figure 2018 Asia Pacific Pulmonary Arterial Hypertension Treatment Market Share by End User
Figure Central & South America Pulmonary Arterial Hypertension Treatment Sales Growth Rate 2014-2019 (K Units)
Figure Central & South America Pulmonary Arterial Hypertension Treatment Revenue Growth Rate 2014-2019 (Million US$)
Table Central & South America Pulmonary Arterial Hypertension Treatment Sales by Countries (2014-2019) (K Units)
Table Central & South America Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries (2014-2019)
Figure 2018 Central & South America Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries
Table Central & South America Pulmonary Arterial Hypertension Treatment Revenue by Countries (2014-2019) (Million US$)
Table Central & South America Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries (2014-2019)
Figure 2018 Central & South America Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries
Figure Brazil Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Brazil Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure Argentina Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Argentina Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Table Central & South America Pulmonary Arterial Hypertension Treatment Sales by Product (2014-2019) (K Units)
Table Central & South America Pulmonary Arterial Hypertension Treatment Sales Market Share by Product (2014-2019)
Figure 2018 Central & South America Pulmonary Arterial Hypertension Treatment Market Share by Product
Table Central & South America Pulmonary Arterial Hypertension Treatment Sales by End User (2014-2019) (K Units)
Table Central & South America Pulmonary Arterial Hypertension Treatment Sales Market Share by End User (2014-2019)
Figure 2018 Central & South America Pulmonary Arterial Hypertension Treatment Market Share by End User
Figure Middle East and Africa Pulmonary Arterial Hypertension Treatment Sales Growth Rate 2014-2019 (K Units)
Figure Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue Growth Rate 2014-2019 (Million US$)
Table Middle East and Africa Pulmonary Arterial Hypertension Treatment Sales by Countries (2014-2019) (K Units)
Table Middle East and Africa Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa Pulmonary Arterial Hypertension Treatment Sales Market Share by Countries
Table Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue by Countries (2014-2019) (Million US$)
Table Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue Market Share by Countries
Figure GCC Countries Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure GCC Countries Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure Turkey Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Turkey Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure Egypt Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure Egypt Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Figure South Africa Pulmonary Arterial Hypertension Treatment Sales Growth Rate (2014-2019) (K Units)
Figure South Africa Pulmonary Arterial Hypertension Treatment Revenue Growth Rate (2014-2019) (Million US$)
Table Middle East and Africa Pulmonary Arterial Hypertension Treatment Sales by Product (2014-2019) (K Units)
Table Middle East and Africa Pulmonary Arterial Hypertension Treatment Sales Market Share by Product (2014-2019)
Figure 2018 Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Share by Product
Table Middle East and Africa Pulmonary Arterial Hypertension Treatment Sales by End User (2014-2019) (K Units)
Table Middle East and Africa Pulmonary Arterial Hypertension Treatment Sales Market Share by End User (2014-2019)
Figure 2018 Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Share by End User
Table GlaxoSmithKline plc Company Details
Table GlaxoSmithKline plc Pulmonary Arterial Hypertension Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table GlaxoSmithKline plc Recent Development
Table Eli Lilly and Company Company Details
Table Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Eli Lilly and Company Recent Development
Table Pfizer Inc.Actelion Inc Company Details
Table Pfizer Inc.Actelion Inc Pulmonary Arterial Hypertension Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Pfizer Inc.Actelion Inc Recent Development
Table United Therapeutic Corporation Company Details
Table United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table United Therapeutic Corporation Recent Development
Table SteadyMed Ltd Company Details
Table SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table SteadyMed Ltd Recent Development
Table Gilead Sciences, Inc Company Details
Table Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Gilead Sciences, Inc Recent Development
Table Teva Pharmaceuticals Inc Company Details
Table Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Teva Pharmaceuticals Inc Recent Development
Table Bayer AG Company Details
Table Bayer AG Pulmonary Arterial Hypertension Treatment Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2014-2019)
Table Bayer AG Recent Development
Table Global Pulmonary Arterial Hypertension Treatment Sales Forecast by Regions 2019-2025 (K Units)
Table Global Pulmonary Arterial Hypertension Treatment Sales Market Share Forecast by Regions 2019-2025
Table Global Pulmonary Arterial Hypertension Treatment Revenue Forecast by Regions 2019-2025 (Million US$)
Table Global Pulmonary Arterial Hypertension Treatment Revenue Market Share Forecast by Regions 2019-2025
Table Global Pulmonary Arterial Hypertension Treatment Sales Forecast by Product 2019-2025 (K Units)
Table Global Pulmonary Arterial Hypertension Treatment Sales Market Share Forecast by Product 2019-2025
Table Global Pulmonary Arterial Hypertension Treatment Revenue Forecast by Product 2019-2025 (Million US$)
Table Global Pulmonary Arterial Hypertension Treatment Revenue Market Share Forecast by Product 2019-2025
Table Global Pulmonary Arterial Hypertension Treatment Sales Forecast by End User 2019-2025 (K Units)
Table Global Pulmonary Arterial Hypertension Treatment Sales Market Share Forecast by End User 2019-2025
Figure North America Pulmonary Arterial Hypertension Treatment Sales Growth Rate Forecast (2019-2025) (K Units)
Figure North America Pulmonary Arterial Hypertension Treatment Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Europe Pulmonary Arterial Hypertension Treatment Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Europe Pulmonary Arterial Hypertension Treatment Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Asia Pacific Pulmonary Arterial Hypertension Treatment Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Asia Pacific Pulmonary Arterial Hypertension Treatment Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Central & South America Pulmonary Arterial Hypertension Treatment Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Central & South America Pulmonary Arterial Hypertension Treatment Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Middle East and Africa Pulmonary Arterial Hypertension Treatment Sales Growth Rate Forecast (2019-2025) (K Units)
Figure Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue Growth Rate Forecast (2019-2025) (Million US$)
Table Pulmonary Arterial Hypertension Treatment Value Chain
Table Pulmonary Arterial Hypertension Treatment Customers List
Table Pulmonary Arterial Hypertension Treatment Distributors List
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
特発性頭蓋内高血圧症治療の世界市場：市場規模・現状・予測 Idiopathic intracranial hypertension is characterized by a buildup of the cerebrospinal fluid causing increase in the blood volume in vessels surrounding the brain and increase in brain swelling. The increase in salt intake causes water retention in the body together with fat adding on to the calori…- 肺薬の世界市場：インサイト・予測 The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or in…
- 肺拡張バルーンの世界市場：インサイト・予測 The pulmonary dilation balloon is a technique used in the treatment of pulmonary valve stenosis. Pulmonary valve stenosis is an abnormality in which there is some deformity on or in the vicinity of the pulmonary valve, and this abnormality slows the blood flow. The global Pulmonary Dilation Balloon …
- 慢性閉塞性肺疾患の世界市場：市場規模・現状・予測 Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow. The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time.The…
- 慢性閉塞性肺疾患の世界市場：市場規模・現状・予測 Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time. Eve…